EP0430999A1

EP0430999A1 - Monoclonal antibody for inhibiting cell infection by hiv viruses

Info

Publication number: EP0430999A1
Application number: EP89909393A
Authority: EP
Inventors: Frank Prof. Dr. Emmrich; Gerhard Prof. Dr. Hunsmann; Wolfgang Dr. Lüke
Original assignee: Deutsches Primatenzentrum GmbH; Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Current assignee: Deutsches Primatenzentrum GmbH; Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date: 1988-08-23
Filing date: 1989-08-22
Publication date: 1991-06-12
Also published as: AU629847B2; DK24891D0; WO1990002199A1; AU4070289A; DK24891A; ES2018387A6; DE3828582A1; JPH04501055A

Abstract

L'anticorps monoclonal 30F16H5T4-MK, que l'on peut obtenir à partir de la ligne de cellules hybrides ECACC 88050502, sert à empêcher l'infection de cellules comportant en leur surface une protéine CD4 par les virus HIV et SIV. Un médicament pour empêcher l'infection par les virus HIV et/ou la propagation des virus dans un corps déjà infecté contient l'anticorps monoclonal 30F16H5, avec, le cas échéant, les véhicules et additifs pharmaceutiques habituels.The 30F16H5T4-MK monoclonal antibody, which can be obtained from the ECACC 88050502 hybrid cell line, is used to prevent infection of cells with CD4 protein on their surface by HIV and SIV viruses. A drug to prevent infection with HIV viruses and / or the spread of viruses in an already infected body contains the monoclonal antibody 30F16H5, with, if necessary, the usual pharmaceutical vehicles and additives.

Description

MonocTonal antibody to inhibit the infection of cells by HIV viruses

Description

The invention relates to a monoclonal antibody, a cell line producing it, and to the use of the monoclonal antibody * ^'for inhibiting Infek¬ tion of cells by the HIV virus.

The HIV virus, also called HTLV-III or LAV-1 virus, is the etiological agent of acquired immune deficiency AIDS. Since the discovery of this virus, medical research worldwide has been trying to find a medicament for the treatment of AIDS, or a way to prevent infection of healthy people. In the medical treatment of already infected, so-called HIV-positive people, who in turn already show severe AIDS symptoms, with substances such as. B. AZT (azidothymidine), which block the formation of DNA complementary to the viral RNA, tries to prevent the reproduction of the viruses and thereby to prevent a further deterioration in the condition of the patients. Such substances which prevent the formation of intact DNA, however, also have negative effects on healthy cells and the side effects which occur during the necessary long-term treatment are considerable. It cannot therefore be said that an effective drug for combating AIDS has already been found. In addition, special attention must be paid to preventing the infection of people who are not yet infected. Some laboratories are already attempting to produce vaccines against the HIV virus for this purpose. With the previously tried However, strategies have not yet succeeded in triggering the formation of antibodies in humans with the formation of so-called memory cells. The formation of the memory cells is necessary so that the body does not remain unprotected against the virus again after the primary immune reaction against the vaccine has subsided, but after infection by the virus these cells can initiate an effective secondary immune reaction.

It is therefore the object of the present invention to create a possibility both to protect uninfected persons from infection by the HIV virus and to prevent the virus from spreading to still healthy cells in infected persons. It is already known from Kowalski et al., Science Vol. 237, pages 1351 to 1355 that the viral surface protein gpl20 binds to the so-called CD-4 protein which is on the surface of, for example, helper T lymphocytes, macrophages and other cells (Dalgleish et al., Nature, 312, (1984), 763; Klatzmann et al., ibid., page 767, McDougal et al., Science 231, 382 (1986)) binds, and thus the Tissue specificity of the viral infection was determined. Analogous to other viruses with a virus envelope, after the binding of gpl20 to CD-4, the virus entry into the cell is facilitated by an envelope-mediated fusion of the viral and target cell membranes.

The invention now relates to a hybridoma cell line, ECACC 88050502, which produces a monoclonal antibody 30F16H5, which in turn is a further subject of the application. This monoclonal antibody binds to the CD-4 protein, which is on the - ^ -

Surface of the target cells of the HIV virus is present and thereby prevents the binding of the viral glycoprotein gpl20 (gpl30 for SIV = simian immunodeficiency virus, a monkey virus closely related to HIV) to the protein and thereby prevents the virus from entering the cell.

The monoclonal antibody is obtained from the hybridoma cell lines by methods known per se, namely the cells are cultivated and the monoclonal antibodies are z. B. obtained from the cell supernatant by protein A Sepharo ^' s chromatography.

Another object of the invention is the use of the monoclonal antibody 30F16H5 to inhibit the infection of cells which have a CD-4 protein on their surface by HIV viruses. By using the antibody of the invention, an initial infection z. B. in particularly vulnerable people by blocking the CD-4 protein for the HIV virus and thus preventing the entry of the virus. However, even after infection has already occurred, the spread of the virus can be prevented by infection of further cells by daughter viruses, as a result of which the virus infection comes to a halt. The already infected cells die after virus multiplication, but the viris can no longer penetrate new cells. There is therefore no progressive destruction of the T cells, which leads to the form of AIDS and death after HIV infection.

Another object of the invention is therefore a medicament for preventing infection by HIV viruses and / or the spread of viruses in the body -

after infection, which contains the monoclonal antibody 30F16H5 according to the invention in a pharmaceutically suitable preparation. Further customary pharmaceutical carriers and additives can be included here. As additives, for example, interferons or interleukins are conceivable, which can contribute to an activation of the immune system and thus for faster neutralization ^"of circulating in the blood of HIV-viruses.

Another object of the invention is a process for the manufacture of a medicament for preventing infection by HIV viruses and / or the spread of the viruses in the body after infection, which is characterized in that the monoclonal antibody 30F16H5 according to the invention is optionally treated with conventional Bring carriers and additives in a pharmaceutically suitable form of use.

Suitable forms of use for the medicament according to the invention are preferably solutions which are suitable for intravenous injection.

According to the invention, by providing the monoclonal antibody 30F16H5 or the hybridoma cell line ECACC 88050502, it is possible to provide a means of blocking the penetration of HIV viruses into their target cells. This can prevent a possible infection, particularly in the case of uninfected persons at risk, or it can prevent the progressive destruction of the entire immune system and thus the lethal consequences of the infection in persons who are already infected.

The following examples further illustrate the invention in conjunction with the figures. - S -

1 shows the autoradiography of an immunoprecipitation with various antisera and monoclonal antibodies;

2 shows the results of a virus neutralization test with the antibody according to the invention.

3 shows the results of a virus neutralization test with various monoclonal antibodies.

Example 1

Immunization and production of the hybridomas for the production of the monoclonal antibody 30F16H5:

4 x 10 to 8 x 10 cells of the human CD4-positive helper T-lymphocyte clone 2C11 (Emmrich & Kaufmann, Infection and Immunity 51 (1986) 879) were thrown three times at intervals of 7 days into female BALB / c- Mice injected intraperitoneally. There was another immunization after three weeks. The same amount of cells was administered intravenously the following day. 3 days after the last injection, the animals were sacrificed and the spleen cells were fused with X63.Ag8.653 myeloma cells according to the method of Köhler and Milstein (Nature 256 (1975) 495) (Kearney et al. J. Immunol. 123 (1979) 1548 ).

After 10 to 14 days, culture supernatants were removed from the growing hybridomas and their antibody activity was examined in functional tests in vitro. The isotype of the antibody 30F16H5 was determined by means of ELISA (Emmrich et al., Eur. J. Immunol. 13 (1983) 273) as mouse IgGl. A sample of the hybridoma cells was deposited with ECACC under the entry number 88050502. The specificity of the antibody 30F16H5 was demonstrated methodically by cell ELISA, APAAP staining and cytofluorometry. Table 1 shows representative results of the use of 1 μg / ml 30F16H5 in binding to three different human cell populations. A lymphoblastoid B cell line was generated by transformation of human B lymphocytes (Steinitz et al., Immunobiology 156 (1979) 41) and used as a homogeneous B cell population. CD4 and CD8 T cells were isolated from human blood using a multistage process (Emmrich et al., Proc. Natl. Acad. Sci. USA 83 (1986) 8298). A Ficoll density gradient was first used to separate the mononuclear cells. Adherent cells were depleted on plastic surfaces, then T-lymphocytes were obtained by rosetting with stabilized sheep erythrocytes. After the erythrocytes had been lysed, the T cells were labeled with commercially available anti-CD4 and anti-CD8 antibodies and, as an antibody, negative populations were separated using a fluorescence-activated cell sorting device. Contamination with other cells was less than 1% for both populations. The labeling with antibodies was carried out according to relevant methods (Gathings et al., Eur. J. Immunol. 7 (1977) 804) using an anti-mouse immunoglobulin antibody which was coupled with FITC (fluorescein isothiocyanate).

Table 1 shows that only CD4 T cells are recognized by the antibody 30F16H5. Since no other population-different antigens other than CD4 and CD8 are known on the cells characterized in this way, it is conclusive that 30F16H5 recognizes the CD4 antigen. This was confirmed by radioimmunoprecipitation experts. - -

Table

1) Control when using a FITC-labeled secondary antibody alone (goat anti mouse Ig with fluorescein)

2) Antibody 30F16H5 and secondary antibody 3) Lymphoblastoid B cell line

Example

Investigations of the inhibition of the binding of 125I-marked gpl30 to cells having CD-4 by various sera or antibodies. ^• Gpl30 was, as described in the European patent application 88 100 191.1. cleaned. The purified gpl30 was iodinated as described in Markwell and Fox (1978), Biochemistry 17, p. 4817 with iodogen as the oxidizing agent. Binding studies were then carried out as follows: 10 Molt-4 cells (human lymphoma) cells were washed three times with RPMI-culture medium ^"(Fa. Gibco) without serum. The cells were washed with 10 cpm of radioiodinated gpl30 ml in the presence or absence of serum or 0.03 0.03 ml (corresponds to 1.5 μg protein) antibody in 0.50 ml RPMI (GIBCO), containing 10% fetal calf serum, incubated for 2 hours at room temperature, then the cells were pelleted and washed four times with 1 ml RPMI without serum. The cell pellet was dissolved in 0.10 ml lysis buffer (10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 2 mM MgCl ₂ , 1 mM DTT (dithiotreitol), 1 mM PMSF (phenylmethylsulfonyl fluoride), 0.5% NP-40 (Nonidet P 40, nonionic detergent)) resuspended and solubilized for 15 minutes at 4 ° C. The lysates were clarified at 10,000 g for 15 minutes. 0.08 ml of the supernatants were mixed with 0.08 ml reaction buffer (1 volume Lysis¬ buffer, 2 volumes of phosphate buffered saline and 0.20 mg / ml ovalbumin), then 0.008 ml of a serum, obtained from a naturally infected green monkey (african green onkey), was added and incubated for 2 hours at 4 ° C. Thereafter, immunoprecipitation was carried out by adding 1 mg of Protein A Sepharose per 0.001 ml of the added serum for 30 minutes. The precipitates were collected by centrifugation and once with high salt wash buffer (20mM Tris-HCl, pH 7.6, 500mM NaCl, 1mM EDTA, 0.5% NP-40 ^' , 1% sodium deoxycholate, 30% sucrose ) and washed twice with wash buffer with low salt content (10 mM Tris-HCl, pH 7.6, 10 mM NaCl). The precipitates were in 0.05 ml sample buffer (0.050 M Tris-HCl, pH 6.8, 0.250 M dithiotreitol, 8,000 M urea, 2,300% SDS ^• and addition of 0.005 μl of a saturated Bro phenolbia solution per 1 ml sample Buffer) and 4 minutes boiled. The Sepharose was then pelleted at 10,000 g for 5 minutes and 0.03 ml of the supernatants were electrophoresed in a 9 to 12% SDS polyacrylamide gradient gel. After electrophoresis, the gel was dried and autoradiography was carried out.

1 shows the autoradiography of such an immunoprecipitation, the individual columns a to m representing the binding of gpl30 to cells carrying CD-4 in the presence of the following antisera or antibodies: a without antiseru, b gpl30 / KLH '/ CFA 'rabbit immune serum c rabbit pre-immune serum (non-immune serum) d gpl30 / GLA ³⁾ / KLH ¹⁾ / ICFA ⁴⁾ rhesus immune serum, two weeks after immunization e gpl30 / KLH 1) / ICFA4) rhesus immune serum, two

Weeks after immunization for serum of a naturally infected green sea cat g serum as d, but 10 weeks after immunization h serum as e, but 10 weeks after immunization i OKT4 monoclonal antibody (company Ortho) j monoclonal antibody Medac T4 ( Medac, Hamburg) k monoclonal antibody Dakopatts T4-MK (Dakopatts)

1 monoclonal antibody 30F16H5 normal human serum according to the invention (without antibody). Keyhole limb hemocyanin

2) complete friend of * adjuvant

³⁾ Glutaraldehyde

4) incomplete Freund's adjuvant

Table 2 shows the results of the measurement of the radioactive radiation of the gpl30 band of FIG. 1 as% inhibition against a control.

T a b e l l e 2

Serum% inhibition

gpl30 / KLH / CFA rabbit immune serum 90

Rabbit preimmune serum 2 gpl30 / GLA / KLH / ICFA Rhesus immune serum, two weeks after

Immunization 51 gpl30 / KLH / ICFA Rhesus immune serum two weeks after immunization 53 serum from a naturally infected green monkey 95 gpl30 / GLA / KLH / ICFA 10 weeks after

Basic immunization 96 gpl30 / KLH / ICFA 10 weeks after basic

Immunization 93

OK 4-MK 24

Medac T4-MK 89

Dakopatt's T4-MK 91

30F16H5 - 95

It can be seen from this that the monoclonal antibody 30F16H5 according to the invention most strongly inhibits the binding of gpl30 to the CD-4 protein of the Molt-4 cells in comparison with the other monoclonal antibodies. - U -

Example 3

Preparation of the antisera used in Example 2.

The anti gpl30 antisera in the rhesus monkey were prepared as described in European patent application 88 100 191.1.

The rabbit antiserum was prepared as follows:

30 μg of the purified gpl30 were mixed with KLH (Hae ocyanin of the keyhole worm) and emulsified in complete Freund's adjuvant (CFA). Half of this emulsion was injected subcutaneously into a rabbit. After 4 weeks, the other half was injected intramuscularly. The antiserum used here was removed 2 weeks after the second injection.

Example 4

Virus neutralization test of the antibody according to the invention.

The neutralization test was carried out according to Harada et al., J. Immun. Meth., 92_ (1986), 77-181, Harada et al., J. Clin. Microbiol. 2, (1985), 908-911. HTLV I-transformed MT4 cells were used for this. det, which are very sensitive to HIV I cytopathogenicity (Harada et al., Science 229 (1985), 563-566). The reduction in viral infectivity was determined by measurement

3 of the (H) -thymidine uptake determined as a marker of cell proliferation. First, the antibody was prediluted from 1:10 to 1: 1280 in Click-RPMI (Biochrom) - 4 -

with 20% inactivated fetal calf serum and 25 mM Hepes. The respective predilutions of the antibody (100 μl) were then mixed with an equal volume of the infectious virus dose. The infectious virus dose is defined as the amount of virus that

3 can reduce the (H) thymidine incorporation of uninfected cells by more than 90%. 50 μl of this mixture were then added to an equal volume of an MT4 cell suspension (6 × 10 cells per ml) in a 96-well microtiter plate. The final dilutions of the antibody then ranged from 1:40 to 1: 5120. The cells were cultivated in Click-RPMI (Biochrom) with 20% fetal calf serum and 25 mM HEPES at 37 ° C. in a 5% CO_ atmosphere. After 3 days, the cells were provided with 100 ul fresh medium. Four days after infection, 0.1 μCi (H) -thymidine was added to the cells. 20 hours later, the cells were collected on glass fiber filters and washed with 10% trichloroacetic acid. The radio activity of the filter was determined. All experiments were carried out three times. 2 AD shows the neutralizing effect of the antibody 30F16H5 according to the invention at various dilutions for the infection of cells by HIV-1-IIIB (FIG. 2A), HIV-2-ben (FIG. 2B), SIVmac (FIG. 2C) ) and SIVagm-TYO-7 (Fig. 2D).

It can be seen from this that the antibody according to the invention is able to suppress the infectivity of HIV I up to a dilution of 1: 1600 and of HIV II up to a dilution of 1: 800 by ^" 75%.

Example 5

Comparison of the virus-neutralizing effect of various antibodies - _Z -

Here too, predilutions of the antibody from 1:10 to 1: 1280 were first prepared in Click-RPMI (Biochrom) with 20% fetal calf serum in 25 mM HEPES. 25 ul of the respective antibody dilution were incubated with 50 ul of an MT4 cell suspension (6x10 cells per ml) for one hour at 37 ° C. The final dilution of the antibody then ranges from 1:30 to 1: 3840. The treated cells were then centrifuged for 10 minutes at 1500 rp in einer.Zentrifuge (Haereus Minifuge), ^• and with the corresponding infectious HIV-1 IIIb dose in 100 ul RPMI click (Fa. Biochrom) with 20% fetal calf serum and 25 M Hepes cultured at 37 ° C in a 5% CO "atmosphere. The further procedure corresponded to Example 4. FIG. 3 shows the neutralizing effect of various commercially available antibodies in comparison with the antibody according to the invention.

Claims

Patent claims. e

1. Hybridoma cell line ECACC 88050502.

2. ^" 30F16H5 monoclonal antibody, available from the hybridoma cell line ECACC 88050502.

3. Use ^"of the monoclonal antibody 30F16H5 for inhibiting the infection of cells having a CD4 protein on their surface, by HIV or SIV viruses.

4. Medicines for preventing infection by HIV or S1 virus or / and the spread of viruses in the body after infection, because of the fact that it contains the monoclonal antibody 30F16H5, if appropriate with conventional pharmaceutical carriers and additives.

5. A process for the manufacture of a medicament for preventing infection by HIV or SlV viruses and / or the spread of the viruses in the body after infection, characterized in that the monoclonal antibody 30F16H5, if appropriate, with conventional carriers and additives in a pharma brings a suitable form of application.